Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM0PETL)

Drug Name
SB-525334 Drug Info
Synonyms
356559-20-1; SB 525334; SB-525334; SB525334; 6-(2-(tert-Butyl)-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; 6-[2-TERT-BUTYL-5-(6-METHYL-PYRIDIN-2-YL)-1H-IMIDAZOL-4-YL]-QUINOXALINE; CHEMBL401570; 6-[2-(1,1-DiMethylethyl)-5-(6-Methyl-2-pyridinyl)-1H-iMidazol-4-yl]quinoxaline; C21H21N5; 6-[2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl]quinoxaline; 6-(2-tert-butyl-5-(6-methylpyridin-2-yl)-1H-imidazol-4-yl)quinoxaline; MLS006011134; SCHEMBL373474; QCR-68; SCHEMBL10000768; CTK4H5088; CHEBI:91391; AOB5969
Cross-matching ID
PubChem CID
9967941
ChEBI ID
CHEMBL401570
CAS Number
CAS 356559-20-1
TTD Drug ID
D03ANS

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Propanoate metabolism 2.39 0.00e+0 30/34 (88.24%) DLD;ALDH6A1;LDHB;...
Glyoxylate and dicarboxylate metabolism 2.21 0.00e+0 23/30 (76.67%) DLD;GLDC;ACAT1;...
Citrate cycle (TCA cycle) 2.15 0.00e+0 30/30 (100%) DLD;IDH3A;SUCLG1;...
Valine, leucine and isoleucine degradation 2.09 0.00e+0 42/48 (87.5%) DLD;AOX1;ALDH6A1;...
Cysteine and methionine metabolism 2.07 0.00e+0 43/50 (86%) GOT1;LDHB;ENOPH1;...
DNA replication 2.03 0.00e+0 34/36 (94.44%) POLD2;MCM2;MCM3;...
One carbon pool by folate 1.97 0.00e+0 15/20 (75%) TYMS;SHMT2;SHMT1;...
Parkinson disease 1.97 1.21e-3 176/249 (70.68%) GNAI1;MAOB;CYCS;...
Ribosome biogenesis in eukaryotes 1.95 1.07e-3 52/108 (48.15%) NOP56;IMP3;RBM28;...
Tyrosine metabolism 1.91 3.87e-3 30/36 (83.33%) AOX1;MAOB;GOT1;...
Glycine, serine and threonine metabolism 1.87 4.40e-3 31/40 (77.5%) DLD;GLDC;MAOB;...
Cell cycle 1.87 4.03e-3 110/124 (88.71%) CDC25B;CDC20;PLK1;...
Spliceosome 1.85 4.46e-3 101/150 (67.33%) SRSF7;HNRNPA1;PRPF8;...
Lysine degradation 1.85 4.15e-3 51/63 (80.95%) DLD;DHTKD1;BBOX1;...
Progesterone-mediated oocyte maturation 1.84 3.87e-3 75/100 (75%) CDC25B;PLK1;ADCY1;...
Proteasome 1.80 5.44e-3 44/46 (95.65%) PSMB9;PSMD6;PSMB8;...
Alanine, aspartate and glutamate metabolism 1.80 5.69e-3 27/37 (72.97%) ASPA;GOT1;GAD1;...
Oxidative phosphorylation 1.79 6.99e-3 93/133 (69.92%) ATP5F1B;ATP6V0E2;NDUFA10;...
Butanoate metabolism 1.77 9.16e-3 23/28 (82.14%) BDH1;ACAT1;HADH;...
Tryptophan metabolism 1.76 1.02e-2 35/42 (83.33%) DLD;AOX1;MAOB;...
RNA transport 1.75 1.01e-2 128/186 (68.82%) PNN;TARDBP;EIF5;...
Oocyte meiosis 1.75 9.67e-3 90/129 (69.77%) CDC20;PLK1;ADCY1;...
Renin-angiotensin system 1.75 9.25e-3 20/23 (86.96%) ENPEP;AGT;ANPEP;...
Drug metabolism 1.73 9.67e-3 78/151 (51.66%) AOX1;MAOB;FMO1;...
Pentose and glucuronate interconversions 1.73 9.67e-3 17/34 (50%) SORD;DCXR;UGT2B28;...
Aminoacyl-tRNA biosynthesis 1.73 9.30e-3 15/66 (22.73%) NARS2;IARS2;CARS2;...
RNA polymerase 1.72 1.04e-2 23/31 (74.19%) POLR3K;POLR2L;POLR2I;...
Pyruvate metabolism 1.68 1.52e-2 41/47 (87.23%) DLD;LDHB;ALDH3A2;...
Starch and sucrose metabolism 1.65 1.97e-2 25/36 (69.44%) GPI;GBA3;GYG1;...
Ribosome 1.64 2.00e-2 113/158 (71.52%) MRPS2;MRPL12;MRPS10;...
Lysosome -1.71 3.15e-2 115/128 (89.84%) ABCA2;NPC1;ATP6V0A2;...
Fc gamma R-mediated phagocytosis -1.71 3.28e-2 79/97 (81.44%) ARF6;PLCG2;ARPC1B;...
NF-kappa B signaling pathway -1.74 2.54e-2 90/104 (86.54%) RELA;TNF;MYD88;...
Prostate cancer -1.76 2.43e-2 93/97 (95.88%) PLAT;PDGFA;TMPRSS2;...
Leishmaniasis -1.79 2.06e-2 67/77 (87.01%) TLR4;MAP3K7;NFKBIA;...
Malaria -1.80 2.06e-2 44/50 (88%) IL1B;THBS4;TLR2;...
Regulation of actin cytoskeleton -1.80 2.15e-2 185/218 (84.86%) ITGB3;SSH1;ITGA3;...
Fluid shear stress and atherosclerosis -1.81 1.95e-2 123/139 (88.49%) MAP2K7;SDC2;CDH5;...
TGF-beta signaling pathway -1.84 1.37e-2 81/94 (86.17%) BMP2;BAMBI;BMPR2;...
AGE-RAGE signaling pathway in diabetic complications -1.84 1.54e-2 97/100 (97%) CDKN1B;KRAS;DIAPH1;...
MicroRNAs in cancer -1.86 1.76e-2 146/310 (47.1%) PRKCA;EFNA4;PDGFA;...
Bladder cancer -1.90 1.03e-2 40/41 (97.56%) SRC;ERBB2;DAPK3;...
Focal adhesion -1.94 6.17e-3 180/201 (89.55%) COL9A2;KDR;MYL12B;...
ECM-receptor interaction -1.94 7.72e-3 80/88 (90.91%) THBS4;COL4A5;SPP1;...
Proteoglycans in cancer -1.94 1.03e-2 172/205 (83.9%) KRAS;ITGB1;FZD8;...
Phagosome -2.08 0.00e+0 118/152 (77.63%) ATP6V0A1;ATP6V0D1;STX12;...
Osteoclast differentiation -2.11 0.00e+0 117/127 (92.13%) SPI1;MAP2K7;PLCG2;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone marrow
Neuroblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SH-SY5Y CVCL_0019 Homo sapiens 0.04uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.04uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-BR-3 CVCL_0033 Homo sapiens 0.08uM - 10uM 6H, 24H
Breast carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BT-20 CVCL_0178 Homo sapiens 0.08uM - 10uM 6H, 24H
Hs 578T CVCL_0332 Homo sapiens 0.08uM - 10uM 6H, 24H
Normal (Epithelial)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HME1 CVCL_2950 Homo sapiens 0.04uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.04uM - 10uM 6H, 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.04uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.04uM - 10uM 6H, 24H
Embryonic stem cell
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUES 3 CVCL_B062 Homo sapiens 0.04uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 0.04uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
1HAEo- CVCL_0128 Homo sapiens 10uM 24H
HEK293 CVCL_0045 Homo sapiens 0.04uM - 10uM 24H
NL20 CVCL_0461 Homo sapiens 10uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 0.04uM - 10uM 6H, 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.04uM - 10uM 6H, 24H
A549/Asc-1 CVCL_YA87 Homo sapiens 0.04uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Fibroblast)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HFL1 CVCL_4295 Homo sapiens 10uM 24H
IMR-90 CVCL_0347 Homo sapiens 10uM 24H
WI-38 CVCL_0579 Homo sapiens 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.04uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.04uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.04uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.04uM - 10uM 6H, 24H
SK-L CVCL_1699 Homo sapiens 0.04uM - 10uM 24H